A Specific Blood Signature Reveals Higher Levels of S100A12: A Potential Bladder Cancer Diagnostic Biomarker Along With Urinary Engrailed-2 Protein Detection.

Elamin, Ayssar A; Klunkelfuß, Saskia; Kämpfer, Susanne; Oehlmann, Wulf; Stehr, Matthias; Smith, Christopher; Simpson, Guy R; Morgan, Richard; Pandha, Hardev; Singh, Mahavir

Elamin, Ayssar A; Klunkelfuß, Saskia; Kämpfer, Susanne; Oehlmann, Wulf; Stehr, Matthias; Smith, Christopher; Simpson, Guy R; Morgan, Richard; Pandha, Hardev; Singh, Mahavir.

Afiliación

Elamin AA; LIONEX Diagnostics and Therapeutics GmbH, Brunswick, Germany.
Klunkelfuß S; LIONEX Diagnostics and Therapeutics GmbH, Brunswick, Germany.
Kämpfer S; LIONEX Diagnostics and Therapeutics GmbH, Brunswick, Germany.
Oehlmann W; LIONEX Diagnostics and Therapeutics GmbH, Brunswick, Germany.
Stehr M; LIONEX Diagnostics and Therapeutics GmbH, Brunswick, Germany.
Smith C; Department of Oncology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom.
Simpson GR; Department of Oncology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom.
Morgan R; Institute of Cancer Therapeutics, Faculty of Life Sciences, University of Bradford, Bradford, United Kingdom.
Pandha H; Department of Oncology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom.
Singh M; LIONEX Diagnostics and Therapeutics GmbH, Brunswick, Germany.

Front Oncol ; 9: 1484, 2019.

Article en En | MEDLINE | ID: mdl-31993369

Palabras clave

EN2; S100A12; bladder; cancer; lateral flow; microarray; plasma; urine

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Front Oncol Año: 2019 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google